Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 89M | 87M | 81M | 80M | 76M |
| Gross Profit | 55M | 52M | 51M | 48M | 43M |
| Operating Income | 2M | 285K | 4M | 7M | 3M |
| EBITDA | -3M | 2M | 6M | 8M | 7M |
| Net Income | -4M | 951K | 5M | 12M | 6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.18
+0.00% today
1Y Change
+62.00%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vaso Corporation (VASO) is a Healthcare stock with a market cap of $30.00M and listed on OTC. The stock last traded around $0.18 and up 62.0% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of +2.7%, EPS growth of +64.8%, a dividend yield of 0.0%. What stands out right now is revenue +2.7%, EPS +64.8%, free cash flow +356.7% with operating margin 2.0% and ROIC -4.0%. Valuation is more restrained than many high-expectation growth names at P/E 21.3 and price/sales 0.4. Stock Foundry combines VASO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VASO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VASO Max Drawdown
-18.40%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VASO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$75.6M
-5.5% YoY
FY Net Income
$6.1M
-48.6% YoY
Free Cash Flow
$7.4M
-46.6% YoY
Revenue Growth
+2.7%
EPS Growth
+64.8%
Gross Margin
61.4%
Net Margin
1.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 89M | 87M | 81M | 80M | 76M |
| Gross Profit | 55M | 52M | 51M | 48M | 43M |
| Operating Income | 2M | 285K | 4M | 7M | 3M |
| EBITDA | -3M | 2M | 6M | 8M | 7M |
| Net Income | -4M | 951K | 5M | 12M | 6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35M | 26M | 11M | 12M | 6M |
| Total Assets | 88M | 83M | 76M | 73M | 52M |
| Total Liabilities | 59M | 55M | 49M | 50M | 41M |
| Shareholder Equity | 29M | 28M | 27M | 23M | 11M |
| Total Debt | 2M | 2M | 2M | 2M | 1M |
| Net Debt | -33M | -24M | -9M | -10M | -5M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
8M
-45.8% YoY
Capital Expenditures
415K
+26.7% YoY
Free Cash Flow
7M
-46.6% YoY
Key ratios
Gross Margin
61.4%
Operating Margin
2.0%
Net Margin
1.8%
ROE
5.7%
Debt / Equity
0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.